The First Step to Getting Your Product to Market: Why Gap Analysis Matters

Bringing a product to market in the life sciences sector is a complex and highly regulated process. Whether you are developing a medical device, a pharmaceutical product, or an advanced therapy, the path to approval is rarely straightforward—particularly in the early stages.

One of the most common questions companies ask is:

“What is the first step in the regulatory process?”

In reality, the first step is not submission, documentation, or even engagement with regulators.

The first step is clarity.

Before any regulatory activity begins, organisations need to understand their current position. Without this, decisions are often based on assumptions rather than facts—leading to delays, increased costs, and unnecessary complexity later in the process.

This is where regulatory gap analysis becomes essential.

A regulatory gap analysis is a structured assessment of your current position against what is required to achieve regulatory approval. It provides a clear view of three critical areas: what you already have in place, what is missing, and what regulators will expect for your product and target market.

Without this level of clarity, progress becomes uncertain. Teams may begin work that is not aligned with regulatory expectations, or overlook key requirements that only become apparent later—often at the most critical stages.

In contrast, a well-executed gap analysis provides a solid foundation. It enables organisations to move forward with confidence, knowing that their strategy is based on a complete and accurate understanding of what is required.

A comprehensive gap analysis will typically include a detailed review of existing documentation, including technical files, clinical or performance data, and quality-related information. It will identify any gaps in evidence or documentation, and assess how these align with the applicable regulatory frameworks in the intended markets.

It will also define the regulatory requirements specific to the product—whether that relates to medical device regulations, medicinal product frameworks, or advanced therapy pathways. From this, a clear and structured pathway to market can be established.

The value of this approach is significant. By identifying gaps early, organisations can reduce risk, avoid costly rework, and make better-informed decisions about timelines and resource allocation. It ensures that effort is focused where it is needed most, rather than spread across assumptions or incomplete strategies.

Ultimately, it transforms uncertainty into a clear and actionable plan.

At BioReg Life Sciences, we provide structured regulatory gap analysis as part of our end-to-end regulatory support. We work with companies across medical devices, pharmaceuticals, and advanced therapies to assess their current position, identify what is missing, and define a clear pathway to market.

Our focus is not simply on progressing regulatory activities, but on ensuring that those activities are built on a strong and well-defined foundation.

Getting a product to market does not start with doing more.

It starts with understanding what is required—and ensuring that nothing critical is overlooked.

For organisations at an early stage, or those unsure of their current regulatory position, a gap analysis is often the most important and most valuable place to begin.